CN107625758A - 虾青素作为胰脂肪酶抑制剂的用途 - Google Patents

虾青素作为胰脂肪酶抑制剂的用途 Download PDF

Info

Publication number
CN107625758A
CN107625758A CN201710799478.9A CN201710799478A CN107625758A CN 107625758 A CN107625758 A CN 107625758A CN 201710799478 A CN201710799478 A CN 201710799478A CN 107625758 A CN107625758 A CN 107625758A
Authority
CN
China
Prior art keywords
astaxanthin
pancreatic lipase
purposes
lipase inhibitor
fat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710799478.9A
Other languages
English (en)
Inventor
杜希萍
邓思
李慧翔
伍菱
董丛丛
黄莹
姜泽东
倪辉
杨远帆
黄高凌
李利君
朱艳冰
肖安风
吴昌正
蔡慧农
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jimei University
Original Assignee
Jimei University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jimei University filed Critical Jimei University
Priority to CN201710799478.9A priority Critical patent/CN107625758A/zh
Publication of CN107625758A publication Critical patent/CN107625758A/zh
Pending legal-status Critical Current

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

本发明公开了虾青素对胰脂肪酶的抑制作用，提供了虾青素的一种新用途。虾青素作为胰脂肪酶抑制剂的用途，其特征是虾青素在减肥药物中的应用。

Description

虾青素作为胰脂肪酶抑制剂的用途
技术领域
本发明公开了虾青素对胰脂肪酶的抑制作用，提供了虾青素的一种新用途，属于医药技术领域。
背景技术
胰脂肪酶是脂肪消化所必需的酶，食物中的脂肪在胰脂肪酶的作用下发生水解，被肠道吸收后，在人体内又重新合成脂肪，作为能量储备。若胰脂肪酶的活性较高，脂肪摄入过多，容易导致人体内脂肪堆积而造成肥胖，从而引发与肥胖相关的疾病如高血脂、糖尿病等。因此，目前市场上出现了针对胰脂肪酶活性抑制的减肥药，其原理是利用胰脂肪酶抑制剂抑制胰脂肪酶的活性，降低肠道中胰脂肪酶对脂肪的催化分解作用，以减少人体对脂肪的吸收，从而达到减肥的目的。但目前市场上许多胰脂肪酶抑制剂存在副作用，如奥利司他对胰脂肪酶有着良好的抑制效果，在临床上作为抗肥胖药物已经被广泛应用，但奥利司他作为一种半合成药物，长期使用会出现胀气、腹泻、脂肪便秘等副作用。
虾青素(3，3′-二羟基-4，4′-二酮基-β，β′-胡萝卜素)作为自然界中广泛存在的一种萜烯类非维生素A源胡萝卜素，其分子式为C40H52O4，归属于叶黄素家族。虾青素具有抗炎活性、抗糖尿病、预防心血管疾病、抗癌活性、免疫调节等生物活性，制药工业已利用虾青素的这些生物活性，开发了多种虾青素的保健产品，但关于虾青素作为减肥药物的开发利用还没有相关文献报道。
发明内容
本发明的目的是提供虾青素作为胰脂肪酶抑制剂在制备减肥药物中的新用途。
虾青素作为胰脂肪酶抑制剂的用途，其特征是虾青素作为胰脂肪酶抑制剂在减肥药物的应用。
其中，虾青素对胰脂肪酶具有抑制作用。
本发明在研究虾青素的作用机制的过程中，发现虾青素对胰脂肪酶具有明显的抑制作用，而胰脂肪酶作为人体肠道中脂肪分解的催化剂，可促进脂肪的分解，分解产物在人体内重新合成脂肪而堆积，虾青素通过抑制胰脂肪酶的活性，可以减少人体对脂肪的摄入而达到减肥的目的。
附图说明
图1为本发明不同来源虾青素对胰脂肪酶的抑制作用。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白，以下结合附图及实施例，对本发明进行进一步详细说明。应当理解，此处所描述的具体实施例仅仅用以解释本发明，并不用于限定本发明。
实施例虾青素对胰脂肪酶活性的抑制率的测定
1、试剂的准备：
Buffer A的配制：准确称量12.10g Tris碱，加入900mL蒸馏水溶解，用浓盐酸缓慢滴定至pH 7.0，再加入5.55g CaCl2并搅拌均匀使其充分溶解，待溶液冷却至室温，用蒸馏水定容到1L。
Buffer B的配制：准确称量0.105g MOPS(3-(N-玛琳代)丙磺酸)，加入45mL蒸馏水使其充分溶解，再加入100μL 0.5mol/L的EDTA的NaOH(0.05mol/L)溶液，100μLNaOH(0.05mol/L)溶液，用盐酸滴定至pH 6.8，放置待溶液冷却后用蒸馏水定容至50mL。
胰脂肪酶液的配制：胰脂肪酶固体以buffer B配制成10U/mL的酶液，高速离心5min，准确称取胰脂肪酶固体0.09g充分溶解于100mL的buffer B溶液中，配制成10U/mL的酶液，冷冻离心5min，取上清液，现配现用。
底物4-硝基苯丁酸酯溶液(p-NPB溶液)的配制：准确称量12.55mg p-NPB，加入10mL二甲基亚砜溶解，配成6mmol/L的p-NPB溶液，于-20℃条件下避光保存备用。
2、虾青素对胰脂肪酶的抑制率的测定
在6支10mL离心管中依次加入60μL的胰脂肪酶酶液、1.7mL buffer A，再分别加入系列浓度为70、50、40、30、10、5μg/mL的虾青素二甲亚砜溶液200μL，37℃保温15min后加入40μL底物p-NPB溶液，37℃继续反应15min后，在405nm处测定吸光值A1。
用buffer B替代酶液，在同一波长下测定其吸光值A2，用二甲基亚砜替代虾青素溶液，测定吸光值A3，用buffer B和二甲基亚砜分别替代酶液和虾青素溶液，测定吸光值A4。
以奥利司他作为阳性对照，儿茶素作为阴性对照，每组实验均测定三次平行。
抑制率按如下公式计算：
为了更加全面地展示本发明所述的测定方法，本实施例对来源不同的几种虾青素的抑制作用均进行了测定和比较，所用的虾青素分别来自法夫酵母、雨生红球藻、化学合成。
通过测定，我们得到如图1所示的结果。从图中可以看出，不同来源的虾青素均对胰脂肪酶有一定的抑制作用，且随着虾青素浓度的增大，抑制率也随之增大。阳性对照奥利司他对胰脂肪酶的抑制活性极强，其IC50值为0.058μg/mL，是一种常见的胰脂肪酶抑制剂。阴性对照儿茶素对胰脂肪酶没有抑制作用。对比三种不同来源的虾青素，在虾青素浓度为70μg/mL时，法夫酵母来源虾青素对胰脂肪酶的抑制率最大为79.42％。通过回归曲线计算得到不同来源虾青素对胰脂肪酶的抑制率IC50值分别为：51.95μg/mL(雨生红球藻)、58.86μg/mL(化学合成)、38.16μg/mL(法夫酵母)。可见，虾青素对胰脂肪酶具有较好抑制作用。
以上所述，仅为本发明较佳的具体实施方式，但本发明的保护范围并不局限于此，任何熟悉本技术领域的技术人员在本发明揭露的技术范围内，可轻易想到的变化或替换，都应涵盖在本发明的保护范围之内。因此，本发明的保护范围应该以权利要求的保护范围为准。

Claims (2)

1.虾青素作为胰脂肪酶抑制剂的用途，其特征在于：虾青素作为胰脂肪酶抑制剂在减肥药物的应用。
2.如权利要求1所述的虾青素作为胰脂肪酶抑制剂的用途，其特征在于：虾青素对胰脂肪酶具有抑制作用。
CN201710799478.9A 2017-09-07 2017-09-07 虾青素作为胰脂肪酶抑制剂的用途 Pending CN107625758A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710799478.9A CN107625758A (zh) 2017-09-07 2017-09-07 虾青素作为胰脂肪酶抑制剂的用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710799478.9A CN107625758A (zh) 2017-09-07 2017-09-07 虾青素作为胰脂肪酶抑制剂的用途

Publications (1)

Publication Number Publication Date
CN107625758A true CN107625758A (zh) 2018-01-26

Family

ID=61100745

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710799478.9A Pending CN107625758A (zh) 2017-09-07 2017-09-07 虾青素作为胰脂肪酶抑制剂的用途

Country Status (1)

Country Link
CN (1) CN107625758A (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11696593B2 (en) 2018-08-24 2023-07-11 Bioscience Formulators, LLC Astaxanthin nutritional compositions and uses

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006059730A1 (ja) * 2004-12-03 2006-06-08 Fuji Chemical Industry Co., Ltd. 体脂肪減少用組成物
US20060287391A1 (en) * 2005-06-15 2006-12-21 Yamaha Hatsudoki Kabushiki Kaisha Phosphodiesterase inhibitor
US20070129436A1 (en) * 2005-12-07 2007-06-07 Yamaha Hatsudoki Kabushiki Kaisha Agent for Suppressing Body Fat Accumulation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006059730A1 (ja) * 2004-12-03 2006-06-08 Fuji Chemical Industry Co., Ltd. 体脂肪減少用組成物
US20060287391A1 (en) * 2005-06-15 2006-12-21 Yamaha Hatsudoki Kabushiki Kaisha Phosphodiesterase inhibitor
US20070129436A1 (en) * 2005-12-07 2007-06-07 Yamaha Hatsudoki Kabushiki Kaisha Agent for Suppressing Body Fat Accumulation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MAYUMI IKEUCHI等: "Effects of Astaxanthin in Obese Mice Fed a High-Fat Diet", 《BIOSCIENCE, BIOTECHNOLOGY, AND BIOCHEMISTRY》 *
SARAVANAN BHUVANESWARI等: "Astaxanthin restricts weight gain, promotes insulin sensitivity and curtails fatty liver disease in mice fed a obesity-promoting diet", 《PROCESS BIOCHEMISTRY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11696593B2 (en) 2018-08-24 2023-07-11 Bioscience Formulators, LLC Astaxanthin nutritional compositions and uses

Similar Documents

Publication Publication Date Title
Landon et al. Impact of astaxanthin on diabetes pathogenesis and chronic complications
Zong et al. Resveratrol inhibits LPS-induced MAPKs activation via activation of the phosphatidylinositol 3-kinase pathway in murine RAW 264.7 macrophage cells
Reiter et al. Melatonin: exceeding expectations
Stolfi et al. Cyclooxygenase-2-dependent and-independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid
Patti et al. Nutraceuticals in lipid-lowering treatment: a narrative review on the role of chitosan
CN105111271B (zh) 一种熊果酸-阿司匹林偶联物及其在制备预防肿瘤转移药物中的应用
Ojha et al. Protective effect of Emblica officinalis (amla) on isoproterenol-induced cardiotoxicity in rats
Calabriso et al. Red grape skin polyphenols blunt matrix metalloproteinase-2 and-9 activity and expression in cell models of vascular inflammation: protective role in degenerative and inflammatory diseases
Tzeng et al. Antioxidant-rich extract from plantaginis semen ameliorates diabetic retinal injury in a streptozotocin-induced diabetic rat model
McIver et al. Acarbose
Miller et al. Infantile acne treated with oral isotretinoin
Dutta et al. Intestinal pathophysiological and microbial changes in sickle cell disease: Potential targets for therapeutic intervention
Checker et al. Sulforaphane, a naturally occurring isothiocyanate, exhibits anti-inflammatory effects by targeting GSK3β/Nrf-2 and NF-κB pathways in T cells
Cheng et al. Muscle wasting in chronic kidney disease: mechanism and clinical implications—a narrative review
He et al. Cinnamaldehyde causes apoptosis of myeloid‑derived suppressor cells through the activation of TLR4
Ferroni et al. Fluorescent light energy (FLE) acts on mitochondrial physiology improving wound healing
CN107625758A (zh) 虾青素作为胰脂肪酶抑制剂的用途
Wen et al. Role of mitophagy in regulating intestinal oxidative damage
Lin et al. Adoptive transfer of DMSO-induced regulatory T cells exhibits a similar preventive effect compared to an in vivo DMSO treatment for chemical-induced experimental encapsulating peritoneal sclerosis in mice
CN106211757A (zh) 使用维甲酸受体激动剂治疗代谢综合征相关病况的方法
Gupta et al. Inhalable particles for “pincer therapeutics” targeting nitazoxanide as bactericidal and host-directed agent to macrophages in a mouse model of tuberculosis
Whitley New approaches to the therapy of HSV infections.
Radha et al. Detection of two distinct types of hemolymphatic prophenoloxidase and their differential responses in the black tiger shrimp, Penaeus monodon, upon infection by white spot syndrome virus
Mao et al. Intestinal barrier function in patients with acute myocardial infarction and the therapeutic effect of glutamine
Jimenez-Saenz et al. Beneficial effects and reversion of vascular lesions by thalidomide in a patient with bleeding portal hypertensive enteropathy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20180126

RJ01 Rejection of invention patent application after publication